tirzepatide 2022 Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA Mounjaro is second obesity drug

Publication bias The statistical approaches for the detection of publication bias or a small-study effect are shown in eFigure 7 in the Supplement

The findings included: Participants with weight/obesity issues for less than 10 years who took 10 mg of tirzepatide lost 21% of their body weight after 72 weeks compared to 20% for those with overweight/obesity for between 10 and 20 years and 23% for those with a disease duration of more than 20 years

Most of the current weight loss drug lawsuits involve GLP-1 medications

Tip: Eating smaller, protein-rich meals and staying hydrated can significantly reduce GI discomfort

Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al

Big Lenny has a condition called Palumboism